AIT Therapeutics (AITB) Upgraded to Hold by Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of AIT Therapeutics (OTCMKTS:AITB) from a sell rating to a hold rating in a research report report published on Tuesday.

According to Zacks, “AIT Therapeutics, Inc. is a clinical-stage anti-microbial therapeutic company using nitric oxide to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections, which are not effectively addressed with current standards of care. It is advancing its revolutionary respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria. AIT Therapeutics, Inc. is based in Ness Ziona, Israel. “

Shares of OTCMKTS AITB opened at $5.16 on Tuesday. The firm has a market cap of $44.75 million, a P/E ratio of -1.71 and a beta of 2.89. AIT Therapeutics has a 12-month low of $2.05 and a 12-month high of $10.00.

AIT Therapeutics (OTCMKTS:AITB) last issued its earnings results on Tuesday, August 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.14). On average, analysts predict that AIT Therapeutics will post -0.93 EPS for the current year.

About AIT Therapeutics

AIT Therapeutics, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.

Recommended Story: Why is insider trading harmful?

Get a free copy of the Zacks research report on AIT Therapeutics (AITB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Pictet Asset Management Ltd. Cuts Holdings in Genomic Health, Inc.
Pictet Asset Management Ltd. Cuts Holdings in Genomic Health, Inc.
TD Ameritrade Holding Corp.  Shares Sold by Pictet Asset Management Ltd.
TD Ameritrade Holding Corp. Shares Sold by Pictet Asset Management Ltd.
SPDR S&P 500 ETF Trust  Position Reduced by Pinkerton Retirement Specialists LLC
SPDR S&P 500 ETF Trust Position Reduced by Pinkerton Retirement Specialists LLC
Schroder Investment Management Group Sells 9,581 Shares of CF Industries Holdings, Inc.
Schroder Investment Management Group Sells 9,581 Shares of CF Industries Holdings, Inc.
Analyzing Bayer  & Savara
Analyzing Bayer & Savara
Arista Networks Inc  Shares Sold by Schroder Investment Management Group
Arista Networks Inc Shares Sold by Schroder Investment Management Group


© 2006-2018 Ticker Report